Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) advises that Neville Mitchell has been appointed as a non-executive director of the company with effect from 12 November 2018.
“We are very pleased to announce Neville’s appointment to the Fisher & Paykel Healthcare Board,” said Chairman Tony Carter. “Neville has extensive global financial and medical device experience and we are looking forward to the significant insights and expertise he will bring to our company.”
Between 1995 and 2017, Mr Mitchell served as Chief Financial Officer and Company Secretary of ASX-listed Cochlear Limited, the world leader in medical device development, manufacture and sale of cochlear implants. Mr Mitchell was a member of Cochlear’s executive team from its listing in 1995 when its annual revenue was A$70 million to its current A$1.3 billion revenue and A$10 billion market capitalisation.
Mr Mitchell is currently a non-executive director of ASX-listed Sonic Healthcare and Osprey Medical, as well as privately owned Australian life sciences company, Q’Biotics Group. He is also a member of the Australian Board of Taxation and a director of the South East Sydney Local Health District Board. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100 (an Australian body for senior finance executives), and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission (ASIC).
The Fisher & Paykel Healthcare board has determined that Mr Mitchell will be an independent director of the Board. He will also serve as a member of the Quality, Safety and Regulatory Committee, effective 12 November 2018. A resolution to elect Mr Mitchell will be put to shareholders at the company’s next annual shareholders’ meeting in August 2019. Mr Mitchell replaces Dr Arthur Morris, who retired from the Board in August 2018.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.